ReviewGut and liver2019
Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease.
Review in Gut and liver, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 2 syntheses or guidelines pooled it, 134 citations in OpenAlex.
- Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials.Frontiers in nutrition · 2025Pooled it
- Network meta-analysis of efficacy and safety of drugs for the treatment of moderate to severe ulcerative colitis.Frontiers in pharmacology · 2024Pooled it
- n-3 Polyunsaturated Fatty Acids Improve DSS-Induced Acute Colitis in Mice via Intestinal Barrier Fortification and Gut Microbiome Modulation.Digestive diseases and sciences · 2026Article
- Progress in targeting the NLRP3 signaling pathway for inflammatory bowel disease (Review).Molecular medicine reports · 2025Review
- Oral olsalazine/ellagic acid/ZnClMaterials today. Bio · 2025Article
- Nanomedicine Strategies in the Management of Inflammatory Bowel Disease and Colorectal Cancer.International journal of molecular sciences · 2025Review
- Dual action tofacitinib-loaded PLGA nanoparticles alleviate colitis in an IBD mouse model.Drug delivery and translational research · 2025Article
- Orally Bioavailable BRD4 BD1 Inhibitor ZL0516 Effectively Suppresses Colonic Inflammation in Animal Models of Inflammatory Bowel Disease.ACS pharmacology & translational science · 2025Article
- Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Sedanolide alleviates DSS-induced colitis by modulating the intestinal FXR-SMPD3 pathway in mice.Journal of advanced research · 2025Article
- Glaucocalyxin A alleviates ulcerative colitis by inhibiting PI3K/AKT/mTOR signaling.Scientific reports · 2025Article
- Cellular Plasticity in Gut and Liver Regeneration.Gut and liver · 2024Review
- Antioxidant Therapy in Inflammatory Bowel Diseases: How Far Have We Come and How Close Are We?Antioxidants (Basel, Switzerland) · 2024Review
- Prebiotic selection influencing inflammatory bowel disease treatment outcomes: a review of the preclinical and clinical evidence.eGastroenterology · 2024Review
- Article
- Approaches, Strategies and Procedures for Identifying Anti-Inflammatory Drug Lead Molecules from Natural Products.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Current Evidence for Combined Targeted Therapy for the Treatment of Inflammatory Bowel Disease.Journal of the Canadian Association of Gastroenterology · 2024Review
- Characteristics and associated factors of health information-seeking behaviour among patients with inflammatory bowel disease in the digital era: a scoping review.BMC public health · 2024Article
- Cutaneous Components Leading to Pruritus, Pain, and Neurosensitivity in Atopic Dermatitis: A Narrative Review.Dermatology and therapy · 2024Review
- LncRNACentral-European journal of immunology · 2024Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New therapeutic strategies in inflammatory bowel disease (IBD) have shifted from symptom control towards treat-to-target algorithms in order to optimize treatment results. The treatment of IBD has evolved with the development of tumor necrosis factor-α inhibitors beyond the conventional therapies. In spite of their long-term effectiveness, many patients do not respond to or cannot sustain treatment with these drugs, which have various side effects. Therefore, the development of new drugs targeting specific pathways in the pathogenesis of IBD has become necessary. Some novel biologics and small molecule drugs have shown potential in IBD clinical trials, providing safe and effective results. In addition, clinicians are now trying to target the dysbiotic microbiome of patients with IBD using fecal microbiota transplantation. New tools such as stem cells have also been developed. The available therapeutic options for IBD are expanding rapidly. In the next few years, physicians will face an unprecedented number of options when choosing the best treatments for patients with IBD. This review provides an overview of recent advances in IBD treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.